Canadian Pharmacist Qualifying Exam Practice · Question
What is the primary therapeutic target for direct oral anticoagulants (DOACs) like rivaroxaban or apixaban?
DOACs like rivaroxaban and apixaban directly inhibit Factor Xa, while dabigatran directly inhibits thrombin. This mechanism distinguishes them from warfarin, wh
Start free practice for Canadian Pharmacist Qualifying Exam Practice
300 questions · no signup required · 40 free questions per day
Question: What is the primary therapeutic target for direct oral anticoagulants (DOACs) like rivaroxaban or apixaban?
Answer options: ✅ Factor Xa or thrombin
- Vitamin K epoxide reductase
- Platelet aggregation
- Prothrombin time (PT)
Correct answer: Factor Xa or thrombin
Explanation: DOACs like rivaroxaban and apixaban directly inhibit Factor Xa, while dabigatran directly inhibits thrombin. This mechanism distinguishes them from warfarin, which inhibits vitamin K epoxide reductase.
Start free practice for Canadian Pharmacist Qualifying Exam Practice
300 questions · no signup required · 40 free questions per day
More about Canadian Pharmacist Qualifying Exam Practice
Related Questions
- Order: 1000 mL D5W over 8 hours. Drop factor 15 gtt/mL. The infusion rate in gtt/min is:
- A pediatric dose is 10 mg/kg q8h for a child weighing 15 kg. Each dose is:
- First-line pharmacotherapy for most patients with type 2 diabetes is:
- First-line treatment of anaphylaxis is:
- A drug has a half-life of 6 hours. If a patient takes a single dose of 100 mg, approximately how much of the d
- Which of the following medications requires genotyping prior to initiation due to pharmacogenomic consideratio
More for Canadian Pharmacist Qualifying Exam Practice candidates
Ready to practice?
Free, no signup required. Build a wrong-question list as you go.
Start Free Canadian Pharmacist Qualifying Exam Practice Practice →Related courses
Other Canadian certifications candidates often prepare for alongside this one.